Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Product Briefs

This article was originally published in The Gray Sheet

Executive Summary

Product news from Revision Optics, Medtronic, Pryor Medical, Interventional Spine and Merit Medical.

You may also be interested in...



FDA Approves Medtronic’s VenaSeal To Treat Venous Reflux

VenaSeal was developed by Sapheon Inc., which Covidien acquired in the summer of 2014 shortly after it announced plans to merge with Medtronic.

Over The Counter 6 Jan 2023: Prebiotics And Consumer Health: Opportunity, Regulation and Future, With Clasado’s Per Rehné

In this episode, HBW Insight interviews Per Rehné, CEO of UK-based microbiome specialists Clasado Biosciences, about the exciting world of prebiotics. Essentially food for your gut microbiome, prebiotics have benefitted from a worldwide boom in preventative health in recent years, as well as a critical mass of clinical research showing the significant role that the gut plays in health, immunity and even stress and anxiety. In this fascinating discussion, Rehné explains the science behind prebiotic supplementation, as well as the regulatory environment in the European Union that makes marketing such supplements challenging, to say the least. We also dive into the current and future growth and innovation opportunities that prebiotics represent for the consumer health industry, which Clasado supplies, as well as marketing its own Bimuno branded product in the UK and beyond.

Advanz Agrees Multi-Market Omalizumab Deal With Alvotech

Advanz and Alvotech have struck a deal that will give Advanz exclusive rights to the biosimilars developer’s Xolair (omalizumab) rival in multiple markets around the world.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel